OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 4 of 33

5 Concomitant Pharmacotherapy Diabetes Mellitus Medications (cont'd) May decrease body weight: • Metformin • GLP-1 RAs (e.g., "-tides") • Dual GLP-1 and glucose-dependent insulinotropic peptide (GIP) agonist • Sodium glucose co-transporter 2 inhibitors (e.g., "-flozins") • Alpha glucosidase inhibitors (e.g., acarbose, miglitol) • Amylin mimetic (pramlintide) Neutral effects on body weight: • Dipeptidyl peptidase-4 (DPP4) inhibitors (e.g., "-gliptins") Metformin • May help improve adiposopathic disorders:   ▶ Insulin resistance   ▶ Polycystic ovary syndrome   ▶ CVD (especially when compared to sulfonylurea) • May help treat complications of concurrent drug treatments:   ▶ Antipsychotic-related weight gain, particularly when started early   ▶ Human immunodef iciency virus (HIV) protease inhibitor- associated abnormalities (i.e., HIV lipodystrophy) • May help reduce the overall cancer rate and help improve the treatment of multiple cancers:   ▶ Colon   ▶ Lung   ▶ Ovary   ▶ Breast   ▶ Prostate • May improve insulin sensitivity and reduce hunger via multifactorial effects such as enhancing the effects of gastrointestinal hormones applicable to weight loss (e.g., increased glucagon-like peptide-1 levels and receptors, increased peptide YY, decreased neuropeptide Y), all of which may facilitate long-term weight loss. Hormones Neutral effects on body weight: • Combined oral contraceptives • Progestin intrauterine devices May increase body weight: • Glucocorticoids (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024